Last reviewed · How we verify

Enbrel — Competitive Intelligence Brief

Enbrel (Enbrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Tumor necrosis factor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Enbrel (Enbrel) — LG Life Sciences.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enbrel TARGET Enbrel LG Life Sciences marketed Tumor necrosis factor
Elrexfio elranatamab-bcmm Pfizer marketed Tumor necrosis factor receptor superfamily member 17 2023-01-01
Trulance PLECANATIDE Salix marketed Guanylate Cyclase-C Agonist [EPC] Tumor necrosis factor 2017-01-01
Lymphostat B BELIMUMAB Human Genome Sciences Inc. marketed B Lymphocyte Stimulator-specific Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 13B 2011-01-01
Prolia DENOSUMAB Amgen marketed RANK Ligand Inhibitor [EPC] Tumor necrosis factor ligand superfamily member 11 2010-01-01
Simponi GOLIMUMAB Centocor Ortho Biotech Inc marketed Tumor Necrosis Factor Blocker [EPC] Tumor necrosis factor 2009-01-01
Abrilada Adalimumab-Afzb AbbVie marketed TNF blocker Tumor necrosis factor-alpha (TNF-alpha) 2002-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enbrel — Competitive Intelligence Brief. https://druglandscape.com/ci/enbrel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: